Strategic Signals Weekly

Evolus, Inc. entered into an exclusive License, Supply and Distribution Agreement with IBSA Institut Biochimique SA for Profhilo®, an injectable hyaluronic acid product for skin-quality applications in the U.S. aesthetics and dermatological fields. Evolus will be responsible for U.S. development, clinical, and regulatory activities to support FDA approval and will purchase the product from IBSA under a transfer-price model post-approval. No upfront or milestone payments are required from Evolus.

Drug: Profhilo · Indication: skin-quality applications in aesthetics and dermatological fields · Partner: IBSA Institut Biochimique SA

Praxis Precision Medicines, Inc. entered into a research collaboration and license agreement with Remagine Labs, Inc. to develop an iontophoretic transdermal patch for ulixacaltamide, targeting essential tremor. This collaboration aims to leverage Remagine's proprietary transdermal drug delivery system to broaden ulixacaltamide's patient reach and strengthen its competitive positioning, complementing Praxis's existing oral program. Praxis also made an equity investment in Remagine.

Drug: ulixacaltamide · Indication: essential tremor · Partner: Remagine Labs, Inc.

Regeneron Pharmaceuticals, Inc. anticipates an acquired in-process research and development (IPR&D) charge of approximately $127 million pre-tax for the second quarter of 2026. This charge stems from upfront and opt-in payments associated with new collaboration and licensing agreements. The company expects this charge to negatively impact both GAAP and non-GAAP net income per diluted share by about $1.00 for the quarter.

RxSight entered into a License, Collaboration and Development Agreement with Alcon Pharmaceuticals, Ltd. to develop and commercialize light-adjustable versions of Alcon's simultaneous vision intraocular lenses (SVIOLs) using RxSight's Light Adjustable Technology. Under the agreement, RxSight will receive a $60 million upfront cash payment, with potential for up to $140 million in additional milestone payments upon achievement of feasibility, FDA submission, and regulatory approval. RxSight will also receive 30% royalties on net sales of the Collaboration Products.

Drug: light-adjustable versions of certain Alcon simultaneous vision intraocular lenses · Indication: intraocular lenses · Partner: Alcon Pharmaceuticals, Ltd

Traws Pharma, Inc. previously entered into an At The Market (ATM) Offering Agreement with Citizens JMP Securities, LLC to sell shares of its common stock for an aggregate sales price of up to $50,000,000. The company is currently limited to offering and selling shares with an aggregate price of up to $5,575,709 under its current "baby shelf" limitation.

Cue Biopharma, Inc. completed a private placement, raising approximately $50.0 million through the issuance of common stock and pre-funded warrants to accredited investors, including Cormorant Asset Management and Columbia Threadneedle Investments. The proceeds are earmarked for clinical development and general corporate purposes. Additionally, the company granted over 1 million restricted stock units to employees, executive officers, and non-employee directors as part of its 2026 Stock Incentive Plan.

Perceptive Capital Solutions Corp (PCSC) has postponed its Extraordinary General Meeting from July 9, 2026, to July 15, 2026. This meeting is for shareholders to approve the Business Combination Agreement with Freenome Holdings, Inc. The postponement allows for supplemental disclosures in the proxy statement/prospectus and additional time for proxy solicitation.

Tarsus Pharmaceuticals, Inc. completed the acquisition of iRenix Medical, Inc. for an upfront consideration of $37.5 million in cash and 607,093 shares of Tarsus common stock. The agreement also includes potential milestone payments up to $490 million for regulatory approval and commercial sales, plus low-to-mid single-digit revenue sharing on future net sales. The stock consideration was issued in a private placement.

MeiraGTx Holdings plc secured up to $375 million through a senior secured royalty note purchase agreement with affiliates of Oberland Capital Management LLC, with an initial $125 million funded. Additionally, the company raised $10 million from a private placement of ordinary shares with Oberland affiliates. The proceeds will be used for working capital, permitted business purposes, and to fully repay existing indebtedness, including the termination of the Perceptive NPA.